Dwight Koeberl
Pediatrics · Durham, NCNPI 1023192184
Payments from drug & device makers
What this record shows
This record is dominated by other: $8,381,904 of the $8,382,233 with a category attached, or 100.0%. Asklepios Biopharmaceutical Inc. accounts for 88.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $3,944,328 and has fallen 100.0% since, to $149 in 2025. Among pediatrics clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $931,359 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asklepios Biopharmaceutical Inc.$7.4M
- Bayer$1M
- Amicus Therapeutics, Inc.$155
- Sanofi$149
- Ultragenyx Pharmaceutical Inc.$23
- Travere Therapeutics, Inc.$2
Across 111 payments — averaging $7764.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$671K
- Ultragenyx Pharmaceutical Inc.$156K
- Sentynl Therapeutics, Inc.$27K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Shire North American Group Inc$2K
What the payments were for
- Food & beverage$3260%
- Education$20%
- Other$8,381,904100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asklepios Biopharmaceutical Inc. | 2 | $7,376,004 |
| Bayer | 1 | $1,005,901 |
| Amicus Therapeutics, Inc. | 1 | $155 |
| Sanofi | 1 | $149 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 3 | $2 |
How this compares
$8,382,233 in reported general payments places this provider in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RavictiGlycerol Phenylbutyrate | 11 | $894,520 |
| LevocarnitineLevocarnitine (With Sugar) | 22 | $4,356 |
| Metronidazole | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other pediatrics in Durham
- Priya KishnaniDurham$5.8M
- Edward SmithDurham$164K
- Daniel LandiDurham$70K
- Rasheed GbadegesinDurham$50K
- Mohamad MikatiDurham$35K
- David VanmaterDurham$32K
- Stephanie DearmeyDurham$30K
- Emmanuel WalterDurham$15K
- William MalcolmDurham$14K
- Charlene WongDurham$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.